MAPK Signal Transduction Underlying Brain Inflammation and Gliosis as Therapeutic Target
暂无分享,去创建一个
Bozena Kaminska | Malgorzata Zawadzka | Maciej Lipko | M. Zawadzka | B. Kamińska | A. Góźdź | A. Ellert-Miklaszewska | M. Lipko | Agata Gozdz | Aleksandra Ellert‐Miklaszewska
[1] Jiahuai Han,et al. Regulation of TNF Expression by Multiple Mitogen-Activated Protein Kinase Pathways1 , 2000, The Journal of Immunology.
[2] Xiaoxia Li,et al. Modulation of Toll–interleukin 1 receptor mediated signaling , 2005, Journal of Molecular Medicine.
[3] J. Wegiel,et al. The role of microglia in amyloid fibril formation. , 1994, Neuropathology and applied neurobiology.
[4] O. Witte,et al. Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion , 1994, Journal of Neuroimmunology.
[5] F. Aloisi. Immune function of microglia , 2001, Glia.
[6] F. Barone,et al. Inflammatory Gene Expression in Cerebral Ischemia and Trauma , 1997, Annals of the New York Academy of Sciences.
[7] M. Block,et al. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism , 2005, Progress in Neurobiology.
[8] S. Miller,et al. Microglia Initiate Central Nervous System Innate and Adaptive Immune Responses through Multiple TLRs1 , 2004, The Journal of Immunology.
[9] J. Dean,et al. Post‐transcriptional regulation of gene expression by mitogen‐activated protein kinase p38 , 2003, FEBS letters.
[10] D. Bozyczko‐Coyne,et al. CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-alpha release from lipopolysaccharide-treated cells and mice. , 2005, European journal of pharmacology.
[11] D E Griswold,et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. , 1996, The Journal of pharmacology and experimental therapeutics.
[12] Kazuhide Inoue,et al. Involvement of P2X4 and P2Y12 receptors in ATP‐induced microglial chemotaxis , 2007, Glia.
[13] M. Zawadzka,et al. A novel mechanism of FK506‐mediated neuroprotection: Downregulation of cytokine expression in glial cells , 2005, Glia.
[14] C. Morissette,et al. Inflammation occurs early during the Aβ deposition process in TgCRND8 mice , 2004, Neurobiology of Aging.
[15] S. Kassis,et al. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. , 2001, The Journal of pharmacology and experimental therapeutics.
[16] N. Rothwell. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential , 2003, Brain, Behavior, and Immunity.
[17] R. Kauppinen,et al. Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[18] Danica Stanimirovic,et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system , 2008, Nature Immunology.
[19] Jerry L. Adams,et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.
[20] C. Palencia,et al. Fibrillar Amyloid-β Peptides Activate Microglia via TLR2: Implications for Alzheimer’s Disease1 , 2008, The Journal of Immunology.
[21] B. Melchior,et al. A rose by any other name? the potential consequences of microglial heterogeneity during CNS health and disease , 2007, Neurotherapeutics.
[22] E. Harhaj,et al. Regulation of the NF-κB-inducing Kinase by Tumor Necrosis Factor Receptor-associated Factor 3-induced Degradation* , 2004, Journal of Biological Chemistry.
[23] J. Hallenbeck,et al. Dual role of tumor necrosis factor alpha in brain injury. , 1999, Cytokine & growth factor reviews.
[24] T. Dawson,et al. Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets , 2001, Annals of neurology.
[25] G. W. Peet,et al. IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program. , 2002, The Journal of biological chemistry.
[26] Andrew D Sharrocks,et al. Transcriptional regulation by the MAP kinase signaling cascades. , 2003, Gene.
[27] Hao Wu,et al. TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.
[28] Carl Nathan,et al. Points of control in inflammation , 2002, Nature.
[29] T. Misteli,et al. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.
[30] J. Rogers,et al. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? , 2007, International review of neurobiology.
[31] M. Karin,et al. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. , 2004, Trends in immunology.
[32] T. Petrova,et al. Selective modulation of BV-2 microglial activation by prostaglandin E(2). Differential effects on endotoxin-stimulated cytokine induction. , 1999, The Journal of biological chemistry.
[33] Michael Schroeter,et al. Inflammation and glial responses in ischemic brain lesions , 1998, Progress in Neurobiology.
[34] M. Gaestel,et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. , 1999, Nature cell biology.
[35] W. Streit,et al. Characterization of microglial reaction after middle cerebral artery occlusion in rat brain , 1993, The Journal of comparative neurology.
[36] R. Nitsch,et al. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia , 2007, Journal of Neuroimmunology.
[37] L. Ivashkiv,et al. Crosstalk among Jak‐STAT, Toll‐like receptor, and ITAM‐dependent pathways in macrophage activation , 2007, Journal of leukocyte biology.
[38] M. Karin,et al. The two NF-κB activation pathways and their role in innate and adaptive immunity , 2004 .
[39] R. Willette,et al. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. , 1997, Stroke.
[40] A. A. Parsons,et al. SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia , 2001, Brain Research.
[41] W. Gan,et al. ATP mediates rapid microglial response to local brain injury in vivo , 2005, Nature Neuroscience.
[42] K. Stokes,et al. Role of T lymphocytes and interferon-gamma in ischemic stroke. , 2006, Circulation.
[43] J. Orange,et al. Interleukin-1-induced NF-κB Activation Is NEMO-dependent but Does Not Require IKKβ* , 2007, Journal of Biological Chemistry.
[44] B. Kamińska. MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits. , 2005, Biochimica et biophysica acta.
[45] G. W. Peet,et al. IKKα, IKKβ, and NEMO/IKKγ Are Each Required for the NF-κB-mediated Inflammatory Response Program* , 2002, The Journal of Biological Chemistry.
[46] A. X. Xie,et al. Modeling CNS microglia: the quest to identify predictive models. , 2008, Drug discovery today. Disease models.
[47] T. Fleisher,et al. Immune function. , 1997, Pediatrics in review.
[48] W. Dietrich,et al. Inflammatory Mechanisms after Ischemia and Stroke , 2003, Journal of neuropathology and experimental neurology.
[49] M. Miller,et al. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. , 1999, The Journal of pharmacology and experimental therapeutics.
[50] David W. Anderson,et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[51] M. Karin,et al. TNFR signaling: ubiquitin‐conjugated TRAFfic signals control stop‐and‐go for MAPK signaling complexes , 2009, Immunological reviews.
[52] C. Palencia,et al. Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease. , 2008, Journal of immunology.
[53] M. Karin,et al. Essential Cytoplasmic Translocation of a Cytokine Receptor–Assembled Signaling Complex , 2008, Science.
[54] R. Kauppinen,et al. β-Amyloid precursor protein transgenic mice that harbor diffuse Aβ deposits but do not form plaques show increased ischemic vulnerability: Role of inflammation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[55] S. Akira,et al. Toll-like Receptors and Type I Interferons* , 2007, Journal of Biological Chemistry.
[56] Michael T. Heneka,et al. Inflammatory processes in Alzheimer's disease , 2007, Journal of Neuroimmunology.
[57] E. Kılıç,et al. TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration , 2008, Neurobiology of Disease.
[58] A. Whitmarsh. Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. , 2007, Biochimica et biophysica acta.
[59] L. Greene,et al. CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family* , 2001, The Journal of Biological Chemistry.
[60] K. Hossmann,et al. Reactive microglia in cerebral ischaemia: an early mediator of tissue damage? , 1995, Neuropathology and applied neurobiology.
[61] K. Tracey,et al. CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[62] T. Mak,et al. Beyond tumor necrosis factor receptor: TRADD signaling in toll-like receptors , 2008, Proceedings of the National Academy of Sciences.
[63] J. Connolly,et al. The Role of mRNA Turnover in the Regulation of Tristetraprolin Expression: Evidence for an Extracellular Signal-Regulated Kinase-Specific, AU-Rich Element-Dependent, Autoregulatory Pathway1 , 2004, The Journal of Immunology.
[64] J. Orange,et al. Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta. , 2007, The Journal of biological chemistry.
[65] M. Nilsson,et al. Astrocyte activation and reactive gliosis , 2005, Glia.
[66] M. Cuzner,et al. Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up‐regulated in Alzheimer's disease , 2002, Journal of neurochemistry.
[67] S. Akira,et al. Pathogen Recognition and Innate Immunity , 2006, Cell.
[68] T. van der Poll,et al. Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia1 , 2002, The Journal of Immunology.
[69] P S Whitton,et al. Inflammation as a causative factor in the aetiology of Parkinson's disease , 2007, British journal of pharmacology.
[70] Deanna L. Taylor,et al. Stimulation of Microglial Metabotropic Glutamate Receptor mGlu2 Triggers Tumor Necrosis Factor α-Induced Neurotoxicity in Concert with Microglial-Derived Fas Ligand , 2005, The Journal of Neuroscience.
[71] J. Dambrosia,et al. Elevated pro-inflammatory CD4+CD28− lymphocytes and stroke recurrence and death , 2004, Neurology.
[72] Matthew Brook,et al. Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 Regulates Tumor Necrosis Factor mRNA Stability and Translation Mainly by Altering Tristetraprolin Expression, Stability, and Binding to Adenine/Uridine-Rich Element , 2006, Molecular and Cellular Biology.
[73] Jeppe Falsig,et al. Specific Modulation of Astrocyte Inflammation by Inhibition of Mixed Lineage Kinases with CEP-13471 , 2004, The Journal of Immunology.
[74] B. Aggarwal. Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.
[75] S. Akira,et al. Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway , 2003, Science.
[76] P. Mcgeer,et al. Inflammation and the Degenerative Diseases of Aging , 2004, Annals of the New York Academy of Sciences.
[77] J. Siekierka,et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. , 1999, The Journal of pharmacology and experimental therapeutics.
[78] Douglas R. McDonald,et al. β-Amyloid Fibrils Activate Parallel Mitogen-Activated Protein Kinase Pathways in Microglia and THP1 Monocytes , 1998, The Journal of Neuroscience.
[79] B. Becher,et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis , 2005, Nature Medicine.
[80] E. Benveniste,et al. Cytokine actions in the central nervous system. , 1998, Cytokine & growth factor reviews.
[81] George Kollias,et al. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses , 2008, Nature Immunology.
[82] B. Kamińska,et al. Targeting signaling pathways with small molecules to treat autoimmune disorders , 2008, Expert review of clinical immunology.
[83] M. Zawadzka,et al. Molecular mechanisms of neuroprotective action of immunosuppressants ‐ facts and hypotheses , 2004, Journal of cellular and molecular medicine.
[84] A. London,et al. Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: The role of innate immunity , 2009, Neuroscience.
[85] W. Scheper,et al. The significance of neuroinflammation in understanding Alzheimer’s disease , 2006, Journal of Neural Transmission.
[86] N. Rothwell,et al. Interleukin 1 in the brain: biology, pathology and therapeutic target , 2000, Trends in Neurosciences.
[87] J. Falsig,et al. The inflammatory transcriptome of reactive murine astrocytes and implications for their innate immune function , 2006, Journal of neurochemistry.
[88] C. Farina,et al. Astrocytes are active players in cerebral innate immunity. , 2007, Trends in immunology.
[89] Guo-Yuan Yang,et al. Reduced Ischemic Brain Injury in Interleukin-1β Converting Enzyme—Deficient Mice , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[90] P. Gasque,et al. "Eat me" and "don't eat me" signals govern the innate immune response and tissue repair in the CNS: emphasis on the critical role of the complement system. , 2003, Molecular immunology.
[91] M. Cobb,et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.
[92] H. Chi,et al. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[93] L. V. Van Eldik,et al. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. , 2007, International review of neurobiology.
[94] A. Steinkasserer,et al. CNI-1493 mediated suppression of dendritic cell activation in vitro and in vivo. , 2004, Immunobiology.
[95] T. Petrova,et al. Selective Modulation of BV-2 Microglial Activation by Prostaglandin E2 , 1999, The Journal of Biological Chemistry.
[96] K. Tracey,et al. An Inhibitor of Macrophage Arginine Transport and Nitric Oxide Production (CNI-1493) Prevents Acute Inflammation and Endotoxin Lethality , 1995, Molecular medicine.
[97] G. Kollias,et al. MK2 Targets AU-rich Elements and Regulates Biosynthesis of Tumor Necrosis Factor and Interleukin-6 Independently at Different Post-transcriptional Levels* , 2002, The Journal of Biological Chemistry.
[98] O. Witte,et al. Lymphocytic Infiltration and Expression of Intercellular Adhesion Molecule-1 in Photochemically Induced Ischemia of the Rat Cortex , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[99] N. Rothwell,et al. Interleukin-1 and inflammatory neurodegeneration. , 2007, Biochemical Society transactions.
[100] K. Nozaki,et al. Activation of Mitogen-Activated Protein Kinases after Transient Forebrain Ischemia in Gerbil Hippocampus , 2000, The Journal of Neuroscience.
[101] H. Kettenmann,et al. Microglia: active sensor and versatile effector cells in the normal and pathologic brain , 2007, Nature Neuroscience.
[102] M. Gaestel,et al. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis , 1999, Nature Cell Biology.
[103] J. Wallace,et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism , 2000, Nature Medicine.
[104] E. Hirsch,et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. , 2008, The Journal of clinical investigation.
[105] Guy C. Brown,et al. Inflammatory Neurodegeneration Mediated by Nitric Oxide from Activated Glia-Inhibiting Neuronal Respiration, Causing Glutamate Release and Excitotoxicity , 2001, The Journal of Neuroscience.
[106] D. Granger,et al. Role of T Lymphocytes and Interferon-γ in Ischemic Stroke , 2006 .
[107] F. Martinon,et al. NLRs join TLRs as innate sensors of pathogens. , 2005, Trends in immunology.
[108] Thomas Hartung,et al. Inhibition of microglial inflammation by the MLK inhibitor CEP‐1347 , 2005, Journal of neurochemistry.
[109] P. Han,et al. Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult , 2003, Journal of neuroscience research.
[110] M. Mattson,et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits , 2007, Proceedings of the National Academy of Sciences.
[111] J. Koistinaho,et al. Interactions between Alzheimer's disease and cerebral ischemia—focus on inflammation , 2005, Brain Research Reviews.
[112] P. Srivastava,et al. Heat shock proteins: the fountainhead of innate and adaptive immune responses , 2000, Cell stress & chaperones.
[113] J. Dean,et al. Post-transcriptional gene regulation by MAP kinases via AU-rich elements. , 2009, Frontiers in bioscience.